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ABSTRACT: This analysis uses data from the Organization for Economic Cooperation and 
Development and other sources to compare health care spending, supply, utilization, prices, 
and quality in 13 industrialized countries: Australia, Canada, Denmark, France, Germany, 
Japan, the Netherlands, New Zealand, Norway, Sweden, Switzerland, the United Kingdom, 
and the United States. The U.S. spends far more on health care than any other country. 
However this high spending cannot be attributed to higher income, an older population, or 
greater supply or utilization of hospitals and doctors. Instead, the findings suggest the higher 
spending is more likely due to higher prices and perhaps more readily accessible technology 
and greater obesity. Health care quality in the U.S. varies and is not notably superior to the 
far less expensive systems in the other study countries. Of the countries studied, Japan has the 
lowest health spending, which it achieves primarily through aggressive price regulation.
                    
INTRODUCTION
Health care spending is a key component of any industrialized country’s economy. It 
provides a major source of employment, often for highly skilled workers and in rural 
areas without other significant industries. In addition, the development of drugs and 
medical technologies can lead to breakthrough products, innovation hubs, and new 
markets. Most important, health spending satisfies fundamental individual and social 
demands for services that bring improved health, greater productivity, and longer lives.
Compared with most other sectors of the economy, a large share of health care 
is publicly funded. In all industrialized countries, with the exception of the United 
States, health care affordability is ensured through universal insurance-based or tax- 
financed systems.1 In the U.S., public funds contribute to health care through 
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insurance programs like Medicare and Medicaid, as well 
as through tax policy that supports employer-sponsored 
health insurance, delivery systems like the Veterans 
Health Administration, and research by the National 
Institutes of Health. Because of the significant public sec-
tor stake in health care, ensuring we receive value for this 
investment is a compelling social concern.
This study updates previous cross-national stud-
ies sponsored by The Commonwealth Fund using health 
data from the Organization for Economic Cooperation 
and Development (see Methods).2,3 It compares health 
care spending, supply, utilization, prices, and quality in 
13 industrialized countries: Australia, Canada, Denmark, 
France, Germany, Japan, the Netherlands, New Zealand, 
Norway, Sweden, Switzerland, the U.K., and the U.S. 
The analysis finds that the U.S. spends more than all 
other countries on health care, but this higher spending 
cannot be attributed to higher income, an aging popu-
lation, or greater supply or utilization of hospitals and 
doctors. Instead, it is more likely that higher spending 
is largely due to higher prices and perhaps more readily 
accessible technology and greater obesity. Despite being 
more expensive, the quality of health care in the U.S. 
appears to be variable, with better-than-average cancer 
survival rates, middling in-hospital mortality rates for 
heart attacks and stroke, and the worst rates of presum-
ably preventable deaths due to asthma and amputations 
due to diabetes compared with the other study countries. 
In contrast, Japan, which has the lowest health spending 
among these countries, controls costs primarily through 
aggressive price regulation—demonstrating the powerful 
correlation between health care prices and total spending.
KEY FINDINGS
Health Care Spending in the U.S. Is Far 
Greater Than in Other Industrialized 
Countries
As previous studies have shown, health care spending in 
the U.S. dwarfs that found in any other industrialized 
country. In 2009, U.S. spending reached nearly $8,000 
per capita. The other study countries spent between 
one-third (Japan and New Zealand) and two-thirds 
(Switzerland and Norway) as much (Exhibits 1 and 2).4 
Note: PPP = Purchasing power parity—an estimate of the exchange rate required to equalize the purchasing 
power of different currencies, given the prices of goods and services in the countries concerned.
Source: OECD Health Data 2011 (Nov. 2011).
Average spending on health
per capita ($US PPP)
Total expenditures on health
as percent of GDP
Exhibit 1. International Comparison of Spending on Health, 1980–2009
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Accounting for differences in national income, the U.S. 
still far outspent the other countries, dedicating more than 
17 percent of its gross domestic product (GDP) to health 
care compared with 12 percent or less in all other coun-
tries. These figures reflect health spending inflation that 
has rapidly surpassed GDP in recent decades.
While there is a positive correlation between 
health spending and per capita income in the 34 member 
countries in the Organization for Economic Cooperation 
and Development (OECD), the higher spending 
observed in the U.S. does not seem primarily attribut-
able to greater income. In the wealthiest of the study 
countries, Norway, health spending accounts for only 
9.6 percent of GDP—nearly 8 percentage points less 
than in the U.S. (Exhibit 2). Based on national income 
and health spending in other OECD countries, a linear 
regression would predict that U.S. health spending would 
be $4,849 per capita or 11 percent of GDP—far less than 
is actually observed.5
Public spending in the U.S. accounted for 
almost half of all health spending in 2009, whereas in 
other countries it accounted for between 60 percent 
(Switzerland) and 84 percent (Norway and the U.K.) 
However, in terms of spending per capita, only Norway 
($4,501) had higher public health care spending than the 
U.S. ($3,795). In fact, public per capita spending in the 
U.S. exceeded total per capita health spending in Sweden, 
the U.K., Australia, New Zealand, and Japan.
U.S. Has Smaller Elderly Population and 
Fewer Smokers, But Higher Obesity Rates
One potential explanation for the high level of U.S. 
health care spending is to attribute it to the aging popula-
tion, as the baby boom generation enters retirement age 
with correspondingly greater health care needs. However, 
this theory does not appear to be borne out. While the 
population is growing older, the U.S. has a relatively 
young population compared with the other study coun-
tries (Exhibit 3). Only 13 percent of the U.S. population 
was older than 65 in 2009, compared with the OECD 
median of nearly 16 percent. New Zealand was the only 
study country with a smaller elderly population than the 
U.S., whereas more than one-fifth of the populations of 
Germany and Japan were over 65. Moreover, the propor-
tion of the U.S. population over age 65 has grown rela-
tively slowly in recent years, rising only 0.5 percent since 
1999, suggesting that an aging demographic has not been 
a primary driver of health spending increases over the 
past decade.
Exhibit 2. Health Spending in Select OECD Countries, 2009
Population 
(millions)
GDP  
per capitab
Total health spending Health spending, by source of financing
Per capitab % GDP Public Private Out-of-pocket
Australia 22.0 $39,924 $3,445a 8.7%a $2,342a $476a $627a
Canada 33.4 $38,230 $4,363 11.4% $3,081 $646 $636
Denmark 5.5 $37,706 $4,348 11.5% — — —
France 62.6 $33,763 $3,978 11.8% $3,100 $587 $291
Germany 81.9 $36,328 $4,218 11.6% $3,242 $424 $552
Japan 127.5 $32,431 $2,878a 8.5%a $2,325a $99a $454a
Netherlands 16.4 $41,085 $4,914 12.0% — — —
New Zealand 4.3 $28,985 $2,983 10.3% $2,400 $184 $399
Norway 4.8 $55,730 $5,352 9.6% $4,501 $43 $808
Sweden 9.3 $37,155 $3,722 10.0% $3,033 $69 $620
Switzerland 7.7 $45,150 $5,144 11.4% $3,072 $504 $1,568
United Kingdom 60.9 $35,656 $3,487 9.8% $2,935 $188 $364
United States 306.7 $45,797 $7,960 17.4% $3,795 $3,189 $976
OECD Median 10.7 $33,434 $3,182 9.5% $2,400 $193 $559
a 2008. 
b Adjusted for differences in cost of living. 
Source: OECD Health Data 2011 (Nov. 2011).
4 The Commonwealth Fund
Lifestyle and behavior are also major determi-
nants of health, which in turn have an impact on health 
care needs and spending. The OECD reports on several 
health-related lifestyle and behavioral indicators, includ-
ing tobacco consumption and obesity. Adults in the U.S. 
were the least likely to be daily smokers than in all of the 
study countries except for Sweden. In 2009, 16 percent 
of U.S. adults were daily smokers compared with the 
OECD median of 21.5 percent (Exhibit 3). In Japan, 
France, and the Netherlands, one-quarter or more of 
the population over age 15 are smokers. Over the past 
decade, smoking rates have declined in all countries 
except the Netherlands.
The story is very different for obesity, which is 
defined as having a body mass index (BMI) equal to 
or greater than 30. One-third of the U.S. population 
is obese—higher than the proportion in any OECD 
country. However, in many countries only self-reported 
data (rather than direct measurements) are available, 
which tend to underestimate obesity. Notably, more than 
one-fifth of the population is also obese in several study 
countries, including New Zealand (27%), where the 
prevalence jumped by nearly 8 percentage points over the 
past decade compared with only 3 percentage points in 
the U.S. (Exhibit 3).
Higher rates of obesity undoubtedly inflate health 
spending; one study estimates the medical costs attribut-
able to obesity in the U.S. reached almost 10 percent of 
all medical spending in 2008.6 However, the younger 
population and lower rates of smoking likely have an 
opposite effect, reducing U.S. health care spending rela-
tive to most other countries.
U.S. Has Below-Average Supply and 
Utilization of Physicians, Hospitals Beds
Another commonly assumed explanation for higher U.S. 
health care spending is that the utilization or supply of 
health care services in the U.S. must be greater than in 
Exhibit 3. Determinants of Health in Select OECD Countries, 2009
Percent of population  
over age 65
Tobacco consumption 
(% population age 15+  
who are daily smokers)
Obesity 
(% population with BMI ≥ 30)
1999 2009 1999 2009 1999 2009
Australia 12.3% 13.3% 22.1%e 16.6%b 21.7% 24.6%b
Canada 12.5% 13.9% 23.8%e 16.2% 13.6%c,d 24.2%a
Denmark 14.9% 16.1% 31.0% 19.0% — —
France 15.9% 16.7% 28.0% 26.2%a 8.2%c,d 11.2%a,c
Germany 16.1% 20.5% 24.7% 21.9% 11.5%c 14.7%c
Japan 16.7% 22.7% 33.6% 24.9% 2.8% 3.9%
Netherlands 13.5% 15.2% 27.8% 28.0% 8.7%c 11.8%c
New Zealand 11.7% 12.8% 26.0% 18.1%b 18.8%e 26.5%b
Norway 15.4% 14.8% 32.0% 21.0% 6%d,c 10.0%a,c
Sweden 17.3% 17.9% 19.3% 14.3% 8.1%c 11.2%c
Switzerland 15.2% 17.2% 28.9%f 20.4%b 6.8%c,e 8.1%b,c
United Kingdom 15.8% 15.8% 27.0%e 21.5% 20.0% 23.0%
United States 12.5% 13.0% 19.2% 16.1% 30.5%f 33.8%a
OECD Median 14.5% 15.8% 26.0% 21.5% — —
Note: BMI = body mass index. 
a 2008. 
b 2007. 
c Self-reported data as opposed to directly measured; tends to underestimate. 
d 1998. 
e 1997. 
f 2000. 
Source: OECD Health Data 2011 (Nov. 2011).
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other countries. OECD data suggest, however, that this 
assumption is unfounded, at least when it comes to phy-
sician and hospital services. There were 2.4 physicians per 
100,000 population in the U.S. in 2009, fewer than in all 
other study countries except Japan. Likewise, patients had 
fewer doctor consultations in the U.S. (3.9 per capita) 
than in any other country except Sweden (Exhibit 4).
Hospital supply and use showed similar trends, 
with the U.S. having fewer hospital beds (2.7 per 1,000 
population), shorter lengths of stay for acute care (5.4 
days), and fewer discharges (131 per 1,000 population) 
than the OECD median (Exhibit 4). Exhibit 5, how-
ever, shows that hospital stays in the U.S. were far more 
expensive than in the other study countries, exceeding 
$18,000 per discharge compared with less than $10,000 
in Sweden, Australia, New Zealand, France, and 
Germany. This could indicate that U.S. hospital stays 
tend to be more resource-intensive than in other coun-
tries or that the prices for hospital services are higher.
Prices for Drugs, Office Visits, and 
Procedures Are Highest in the U.S.
Exhibit 6 shows prices for selected health services and 
products to be higher in the U.S.—far higher, in some 
cases—than in the other study countries. According to an 
analysis by Gerard Anderson of IMS Health data, U.S. 
prices for the 30 most-commonly prescribed drugs are 
one-third higher than in Canada and Germany, and more 
than double the prices in Australia, France, Netherlands, 
New Zealand, and the U.K. (Exhibit 6).7 Notably, prices 
for generic drugs are lower in the U.S. than in these other 
countries, whereas prices for brand-name drugs are much 
higher.
Spending on physician services is an even larger 
component of total health spending than pharma-
ceuticals. In an analysis published in Health Affairs in 
2011, Miriam Laugesen and Sherry Glied found U.S. 
primary care physicians generally receive higher fees for 
office visits and orthopedic physicians receive higher 
fees for hip replacements than in Australia, Canada, 
Exhibit 4. Supply and Utilization of Doctors and Hospitals in Select OECD Countries, 2009
Physician supply and use Hospital supply and use
Practicing  
physicians per 
100,000 population
Doctor 
consultations  
per capita
Acute care hospital 
beds per 1,000 
population
Average length of 
stay for acute care 
(days)
Hospital 
discharges per 
1,000 population
Australia 3.0a 6.5 — 5.9a 162a
Canada — 5.5a 1.8a 7.7a 84a
Denmark 3.4a 4.6 2.9 — 170
France — 6.9 3.5 5.2 263
Germany 3.6 8.2 5.7 7.5 237
Japan 2.2a 13.2a —d —d —d
Netherlands — 5.7 3.1 5.6 117
New Zealand 2.6 4.3b — 5.9a 142a
Norway 4.0 — 2.4 4.6 177
Sweden 3.7a 2.9 2.0 4.5 166
Switzerland 3.8 4.0b 3.3 7.5 168
United Kingdom 2.7 5.0 2.7 6.8 138
United States 2.4 3.9a 2.7b 5.4 131a
OECD Median 3.0 6.3 3.2 5.9 160
a 2008. 
b 2007. 
c Adjusted for differences in cost of living. 
d A significant amount of hospital care is dedicated to long-term care in Japan, making cross-national comparison difficult. 
Source: OECD Health Data 2011 (Nov. 2011).
6 The Commonwealth Fund
Exhibit 5. Hospital Spending per Discharge, 2009
Adjusted for Differences in Cost of Living
* 2008.
** 2007.
Source: OECD Health Data 2011 (Nov. 2011).
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Exhibit 6. Drug Prices and Physician Fees in Select OECD Countries
Prices for 30 most commonly  
prescribed drugs, 2006–07 
(U.S. set at 1.00)a
Primary care physician fee  
for office visits, 2008b,c
Orthopedic physician fee for  
hip replacements, 2008b,c
Brand  
name Generic Overall
Public  
payer
Private  
payer
Public  
payer
Private  
payer
Australia 0.40 2.57 0.49 $34 $45 $1,046 $1,943
Canada 0.64 1.78 0.77 $59 — $652 —
France 0.32 2.85 0.44 $32 $34 $674 $1,340
Germany 0.43 3.99 0.76 $46 $104 $1,251 —
Netherlands 0.39 1.96 0.45 — — — —
New Zealand 0.33 0.90 0.34 — — — —
Switzerland 0.51 3.11 0.63 — — — —
United Kingdom 0.46 1.75 0.51 $66 $129 $1,181 $2,160
United States 1.00 1.00 1.00 $60 $133 $1,634 $3,996
Median (countries shown) 0.43 1.96 0.51 $53 $104 $1,114 $2,052
a Source: Analysis by G. Anderson of IMS Health data. 
b Adjusted for differences in cost of living. 
c Source: M.J. Laugesen and S.A. Glied, “Higher Fees Paid to U.S. Physicians Drive Higher Spending  
for Physician Services Compared to Other Countries,” Health Affairs, Sept. 2011 30(9):1647–56.
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France, Germany, and the U.K. (Exhibit 6).8 This was 
true whether the payers were public or private, though 
in every country private payers paid higher fees than 
public payers (where data was available). Not surprising, 
Laugesen and Glied also found that U.S. primary care 
doctors ($186,582) and particularly orthopedic doctors 
($442,450) earned greater income than in the other five 
countries (Exhibit 7).
Use of Expensive Medical Technology 
More Common in the U.S.
The final potential explanation for high U.S. health 
spending considered in this study is greater use of more 
expensive medical technology than other countries. The 
OECD tracks the volume of several types of procedures, 
including hip and knee replacements—two gener-
ally elective procedures that involve expensive medical 
devices. In 2009, the U.S., along with Germany, per-
formed the most knee replacements (213 per 100,000 
population) among the study countries, and 75 percent 
more knee replacements than the OECD median (122 
per 100,000 population). However, the U.S. performed 
barely more hip replacements than the OECD median, 
and significantly less than several of the other study 
countries (Exhibit 8).
The OECD also tracks the supply and utilization 
of several types of diagnostic imaging devices—important 
and often costly technologies. Relative to the other study 
countries where data were available, there were an above-
average number of magnetic resonance imaging (MRI) 
machines (25.9 per million population), computed 
tomography (CT) scanners (34.3 per million), positron 
emission tomography (PET) scanners (3.1 per million), 
and mammographs (40.2 per million) in the U.S. in 
2009 (Exhibit 9). Utilization of imaging was also highest 
in the U.S., with 91.2 MRI exams and 227.9 CT exams 
per 1,000 population. MRI and CT devices were most 
prevalent in Japan, though no utilization data were avail-
able for that country.
The International Federation of Health Plans—a 
membership organization of health insurance companies 
from over 30 countries—issues an annual report tracking 
Exhibit 7. Physician Incomes, 2008
Adjusted for Differences in Cost of Living
Source: M. J. Laugesen and S. A. Glied, “Higher Fees Paid to U.S. Physicians Drive Higher Spending for Physician Services 
Compared to Other Countries,” Health Affairs, Sept. 2011 30(9):1647–56.
Dollars
186,582
Primary care doctors Orthopedic physicians
0
100,000
200,000
300,000
400,000
500,000
AUSFRCANGERUKUS FRAUSGERCANUKUS
159,532
131,809 125,104
95,585 92,844
442,450
324,138
208,634 202,771
187,609
154,380
8 The Commonwealth Fund
Exhibit 8. Volume of Knee and Hip Replacements, 2009
* 2008.
** 2007.
Source: OECD Health Data 2011 (Nov. 2011).
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Exhibit 9. Diagnostic Imaging in Select OECD Countries
MRI machines CT scanners PET scanners Mammographs
Devices per 
million pop., 
2009c
Exams per 
1,000 pop., 
2009c
MRI scan 
fees, 
2011d
Devices per 
million pop., 
2009c
Exams per 
1,000 pop., 
2009c
CT scan 
(head) 
fees, 2011d
Devices per 
million pop., 
2009c
Devices per 
million pop., 
2009c
Australia 5.9 23.3 — 38.7 93.9 — 1.1 24.3
Canada 8.0 43.0 — 13.9 125.4 $122e 1.1 —
Denmark 15.4 37.8a — 23.7 83.8a — 5.6 17.0
France 6.5 55.2 $281 11.1 138.7 $141 0.9 —
Germany — — $599 — — $272 — —
Japan 43.1a — — 97.3a — — 3.7a 29.7a
Netherlands 11.0 43.9 — 11.3 65.7 — 4.5 —
New Zealand 9.7 — — 14.6 — — 0.5 26.4
Switzerland — — $903 32.8 — $319 3.0 33.2
United Kingdom 5.6a — — 7.4a — — — 9.0
United States 25.9b 91.2b $1,080f 34.3b 227.9b $510f 3.1a 40.2a
Median  
(countries shown)
8.9 43.0 — 15.1 122.8 — 1.1 17.3
a 2008. 
b 2007. 
c Source: OECD Health Data 2011 (Nov. 2011). 
d Source: International Federation of Health Plans, 2011 Comparative Price Report: Medical and Hospital Fees by Country (London: IFHP, 2011). 
e Nova Scotia only. 
f U.S. commercial average.
Explaining High Health Care Spending in the United States: An International Comparison 9
health care prices around the world.9 Data from their 
2011 report indicate that the U.S. commercial average 
diagnostic imaging fees ($1,080 for an MRI and $510 for 
a CT exam) are far higher than what is charged in almost 
all of the other countries (Exhibit 9). This combination 
of pervasive medical technology and high prices show-
cases two potent drivers of U.S. health spending, and a 
possible explanation for the outsized share of resources 
we dedicate to health care relative to the rest of the world.
Despite High Health Care Spending, 
Quality Indicators Show Variable 
Performance in the U.S.
An array of health care quality indicators included in the 
2011 OECD Health Data database provides insight into 
the performance of each country’s health care system. 
The findings make clear that, despite high costs, quality 
in the U.S. health care system is variable and not notably 
superior to the far less expensive systems in the other 
study countries.
Exhibit 10 shows the five-year survival rates for 
breast, cervical, and colorectal cancers. The U.S. had 
the highest survival rates among the study countries for 
breast cancer (89%) and, along with Norway, for colorec-
tal cancer (65%). However, at 64 percent, the survival 
rate for cervical cancer in the U.S. was worse than the 
OECD median (66%), and well below the 78 percent 
survival rate in Norway—indicating significant room for 
improvement. Notably, the U.K. had the lowest survival 
rates for all three forms of cancer.
Exhibit 11 shows rates of potentially preventable 
mortality due to asthma (for those between ages 5 and 
39) and lower-extremity amputations due to diabetes per 
100,000 population. On both measures, the U.S. had 
among the highest rates, suggesting a failure to effec-
tively manage these chronic conditions that make up 
an increasing share of the disease burden.10 Exhibit 11 
also shows rates of in-hospital fatality rates—that is, the 
ratio of in-hospital deaths among people admitted with 
a particular condition—within 30 days of admission for 
Exhibit 10. Five-Year Survival Rate for Select Cancers, 2004–2009
Note: Breast and cervical cancer rates are age-standardized; colorectal cancer rates are age–sex standardized.
* 2003–08.
** 2002–07.
Source: OECD Health Data 2011 (Nov. 2011).
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acute myocardial infarctions and ischemic and hemor-
rhagic stroke.11 U.S. performance on these measures was 
middling: the fatality rate for acute myocardial infarc-
tions was roughly average in the U.S. (4.3 deaths per 100 
patients) compared with the study countries, the rate for 
ischemic stroke (3.0 deaths per 100 patients) was some-
what better than average, and the rate for hemorrhagic 
stroke (21.0 deaths per 100 patients) was somewhat 
worse than average.
DISCUSSION
U.S. health care spending, which reached nearly $8,000 
per person annually in 2009, has outpaced GDP growth 
for the past several decades and far exceeds spending in 
any other country. The analysis in this brief suggests that 
this spending cannot be attributed to higher income, an 
aging population, or greater supply or utilization of hos-
pitals and doctors. Instead, it is more likely that higher 
spending is largely due to higher prices and perhaps 
because of more readily accessible technology and greater 
rates of obesity. Despite being more expensive, the quality 
of health care in the U.S. does not appear to be notably 
superior to other industrialized countries.
Such an expensive health system creates an enor-
mous financial strain and can pose a barrier to accessing 
care. For many U.S. households, health care has become 
increasingly unaffordable. In 2010, four of 10 adults 
went without care because of costs and the number of 
either uninsured or “underinsured” (i.e., people with 
health coverage that does not adequately protect them 
from high medical expenses) increased to more than 80 
million.12 A 2007 survey in five states found that dif-
ficulty paying medical bills contributed to 62 percent 
of all bankruptcies, up 50 percent from 2001.13 For the 
average worker with employer-based health insurance, 
growth in premiums and cost-sharing has largely erased 
wage gains over the past decade.14
Exhibit 11. Quality Indicators in Select OECD Countries, 2009
Asthma mortality 
among ages 5 to 
39 per 100,000 
population
Diabetes lower 
extremity amputations 
per 100,000 
population
In-hospital fatality rate within 30 days of admission  
per 100 patientsc
Acute myocardial 
infarction
Ischemic 
stroke
Hemorrhagic 
stroke
Australia 0.13 11.0 3.2 5.7 17.2
Canada 0.17b 9.5 3.9 6.3 20.6
Denmark 0.08 18.1 2.3 2.6 16.4
France — 12.6b — — —
Germany 0.17b 33.7 6.8 4.0 13.8
Japan — — 9.7a 1.8a 9.7a
Netherlands 0.09a 12.0b 5.3b 5.7b 22.5b
New Zealand 0.43b 7.0 3.2 5.4 21.1
Norway 0.27 9.9 2.6 2.8 11.6
Sweden 0.01a 5.7 2.9b 3.9b 12.8
Switzerland — 7.4a 4.5a — 14.8a
United Kingdom 0.27 4.8 5.2 6.8 19.3
United States 0.40b 32.9a 4.3a 3.0a 21.0a
OECD Median 0.09 9.9 4.6 4.9 19.3
Note: Rates are age–sex standardized. 
a 2008. 
b 2007. 
c Figures do not account for death that occurs outside of the hospital, possibly influencing  
the ranking for countries, such as the U.S., that have shorter lengths of stay. 
Source: OECD Health Data 2011 (Nov. 2011).
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Rising health care spending has a profound 
effect on public budgets as well. Federal spending on 
Medicare and Medicaid increased from 1 percent to 5 
percent of GDP between 1970 and 2009, and is pro-
jected to reach 12 percent by 2050.15 The Congressional 
Budget Office has identified it as the primary cause of 
projected federal budget deficits.16 Medicaid spending 
also impacts state budgets, increasing faster than and 
potentially crowding out other socially desirable budget 
items, such as education and infrastructure.
While all the countries in this study struggle in 
one way or another with health care costs, financing 
the U.S. health system requires a unique commitment 
of resources. Were the U.S. to spend the same share of 
GDP on health care as the Netherlands—the country 
spending the next-largest share of GDP—savings for the 
nation as a whole would have been $750 billion in 2009 
alone. Were the U.S. to spend the same share of GDP 
as Japan, savings would have totaled $1.25 trillion—an 
amount larger than the U.S. defense budget.
As the lowest-spending nation in this study, 
Japan offers an interesting contrast to the U.S. In some 
ways, the two countries’ health systems share similar 
features. Japan operates a fee-for-service system, char-
acterized by unrestricted access to specialists and hospi-
tals.17 Advanced medical technology also appears to be 
widely available, with Japan having the most CT scan-
ners and MRI machines among the countries in this 
study. Yet health spending in Japan as a share of GDP 
has increased by only 2 percentage points in the past 
three decades, compared with an increase of more than 
8 percentage points in the U.S. over the same period.
Notably, the Japanese do not restrain spending 
by restricting access; rather, they do so by aggressively 
regulating health care prices.18 Every two years, a panel 
of experts uses volume projections to revise the national 
fee schedule, which determines the maximum prices for 
nearly all health services, to keep total health spending 
growth within a target set by the central government. 
Providers’ profitability is also monitored, and when 
certain categories of providers (e.g., acute care hospitals 
or ambulatory specialists) demonstrate significantly 
greater profitability than the average, prices for their 
services are reduced. Despite such overt price controls, 
the results are hard to dispute—the Japanese enjoy the 
longest life expectancy in the world.
In the U.S., private payers individually negotiate 
prices with health care providers, in a process character-
ized by administrative complexity and a lack of trans-
parency. For example, hospitals often charge different 
payers widely varying prices that are, on average, far 
below those listed on hospitals’ official price lists.19 The 
economist Uwe Reinhardt and others have argued that 
such price discrimination is not in the public interest, 
and that an all-payer system—as in Japan, Germany, 
and several other nations—would be more equitable, 
efficient, and potentially effective at reining in spending 
growth.20 Such a system is not completely foreign to the 
U.S. The state of Maryland has operated an all-payer 
system for hospitals since 1977, and has seen costs per 
admission rise slower than the national average.21
Inevitably, efforts to control health care spend-
ing involve trade-offs, and many such efforts—whether 
restricting access or regulating prices—come with a 
cost. Lower drug prices may lead to less research and 
development and, consequently, fewer pharmaceutical 
breakthroughs. Lower provider incomes could reduce 
the quality of applicants choosing a career in medi-
cine. These drawbacks need to be measured against the 
opportunity costs of health care crowding out other 
forms of public investment, and of vulnerable house-
hold budgets being exposed to the most expensive 
health care system in the world.
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